Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 4.92% and -4.12%, respectively, for the quarter ended June 2018. Flexion Therapeutics Inc. published this content on 08 September 2020 and is solely responsible for the information contained therein. Want to see which stocks are moving? Which way to trade Flexion Mobile (STO:FLEXM)? The company hosted a conference call on October According to TipRanks.com, Trucchio is a 2-star analyst with an average return of 1.6% and a 40.0% success rate. Recent executive movements at Flexion Therapeutics. FX201 (humantakinogene hadenovec) FX201 is a novel, intra-articular gene therapy product candidate which utilizes a helper-dependent adenovirus (HDAd) vector based on human serotype 5 (Ad5) that is designed to transfer a … (AP) _ Flexion Therapeutics Inc. (FLXN) on Wednesday reported a loss of $24.6 million in its third quarter. Learn more. Flexion Therapeutics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Flexion Therapeutics Inc. (NASDAQ: FLXN) is -37.15% lower on its value in year-to-date trading and has touched a low of $5.01 and a high of $22.98 in the current 52-week trading range. News. Comparing Flexion Therapeutics, Inc.'s CEO Compensation With the industry. Learn more. Share your opinion and gain insight from other stock traders and investors. Sector Healthcare RiskRating. ET by Emma Court Flexion Therapeutics started at … Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million Provided by GlobeNewswire Oct 13, 2020 10:59 AM UTC GlobeNewswire BURLINGTON, Mass. Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights finance.yahoo.com - August 5 at 6:35 PM: Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020 finance.yahoo.com - July 30 at 5:55 PM: Flexion Therapeutics (FLXN) Is Up 9.84% in One Week: What You Should Know Flexion (FLXN) Soars: Stock Adds 6.6% in Session, Planning For A Rebound In Flexion Therapeutics, Why Flexion Therapeutics Is Tumbling 10% Today, Flexion under pressure after pricing equity offering, Flexion Therapeutics Announces Pricing of Public Offering of Common Stock, Flexion Therapeutics Announces Proposed Public Offering of Common Stock, How Flexion Therapeutics (FLXN) Stock Stands Out in a Strong Industry, Flexion Therapeutics to Present at the RBC Capital Markets 2020 Virtual Global Healthcare Conference, Flexion Therapeutics Inc (FLXN) Q1 2020 Earnings Call Transcript, Edited Transcript of FLXN earnings conference call or presentation 7-May-20 8:30pm GMT, Receive Analysts' Upgrades and Downgrades Daily. © 2020 Verizon Media. Recent News. Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million Provided by GlobeNewswire Oct 13, 2020 10:59 AM UTC GlobeNewswire Share Price & News. Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. Flexion Therapeutics News: This is the News-site for the company Flexion Therapeutics on Markets Insider Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. BURLINGTON, Mass., April 01, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has entered into an exclusive license agreement with HK Tainuo and Jiangsu Tainuo (a subsidiary of China Shijiazhuang Pharmaceutical Co, Ltd.) for the development and commercialization of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in … Are Options Traders Betting on a Big Move in Flexion (FLXN) Stock? Learn everything you need to know about successful options trading with this three-part video course. Latest Share Price and Events. Please log in to your account or sign up in order to add this asset to your watchlist. Flexion Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference. Looking for new stock ideas? Get short term trading ideas from the MarketBeat Idea Engine. Year-to-date, Flexion Therapeutics Inc (NASDAQ:FLXN) stock lost 42.1% and on October 30th it … Year-to-date, Flexion Therapeutics Inc (NASDAQ: FLXN ) stock lost 42.1% … GlobeNewswire. © American Consumer News, LLC dba MarketBeat® 2010-2020. View detailed financial information, real-time news, videos, quotes and analysis on Flexion Therapeutics, Inc. (NASDAQ:FLXN). Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. Flexion’s strategy is to build a robust pipeline of locally administered therapies to address musculoskeletal conditions, with an initial focus on osteoarthritis (OA). Flexion shares halted on news of FDA approval for knee pain injection Oct. 6, 2017 at 3:10 p.m. The results did not meet Wall Street expectations. BURLINGTON, Mass. BURLINGTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units. BURLINGTON, Mass. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. 10/29: Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on Novemb.. GL. Date Time Source Headline; 20/8/2020: 21:48: EDGAR: Statement of Changes in Beneficial Ownership (4) 20/8/2020: 21:46: EDGAR: Initial Statement of Beneficial Ownership (3) 19/8/2020: 22:01: EDGAR: Current Report Filing (8-k) 19/8/2020: 14:00: GLOBE : Flexion Therapeutics Announces Appointment of Liz Kwo, MD, to its Board … Flexion resumed enrollment in Phase 1 dose-escalation trial for FX201; FX301 on track to enter clinic in 2021; BURLINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for … BURLINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the H.C. Wainwright Virtual Healthcare Conference. Flexion Therapeutics, Inc. (FLXN) has a 52 week range of $5.01 to $22.98. Share Price & News. Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference. Our data indicates that Flexion Therapeutics, Inc. has a market capitalization of US$615m, and total annual CEO compensation was reported as US$3.8m for the year to December 2019. Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. Identify stocks that meet your criteria using seven unique stock screeners. Flexion Therapeutics, Inc. (FLXN) Stock Price: $11.98 USD 0.01 (0.08%) Updated Sep 18, 2020 4:00 PM EDT - Market closed. Flexion Therapeutics Announces Publication of New Abstracts Accepted at Osteoarthritis Research Society International OARSI 2020 GlobeNewswire 213d Flexion Therapeutics to Report First … How has Flexion Therapeutics's share price performed over time and what events caused price changes? Company's 52-week high was at $22.98. Adventurous. The company’s shares closed last Friday at $10.82. All rights reserved. Flexion Therapeutics, Inc. (NASDAQ:FLXN) traded at $10.9 at last check on Friday, Nov 06, making a downturn move of -7.16% on its previous day’s price. View our latest analysis for Flexion Therapeutics . The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field. Flexion Therapeutics, which belongs to the Zacks Medical - Drugs industry, posted revenues of $23.66 million for the quarter ended September 2020, surpassing the … In the final minutes of trading on Wednesday, shares hit $12.97, a decline of 26% in the last 12 months. Flexion’s strategy is to build a robust pipeline of locally administered therapies to address musculoskeletal conditions, with an initial focus on osteoarthritis (OA).
Best Fly Traps For Outside, Grey Color Nail Polish, Mediacorp Enable Fund Application Form, Pagan Ethos Meaning, Tune Hisense Tv Without Remote, Thumper Massager Pro, Cat 6e Cable Price, Aurora Definicion In English,